Neokleous Nikolaos, Sideri Anastasia, Peste-Tsilimidos Corina
Hematological Clinic, General Hospital of Limassol, Cyprus;
Hematol Rep. 2011 Jan 13;3(1):e6. doi: 10.4081/hr.2011.e6. Epub 2011 Jun 14.
Over the last two decades umbilical cord blood (UCB) transplantation (UCBT) is increasingly used for a variety of malignant and benign hematological and other diseases. The main factor that limits the use of UCB to low weight recipients, mainly children and adolescents, is its low progenitor cell content. Various alternatives have been exploited to overcome this difficulty, including the transplantation of two UCB units (double umbilical cord blood transplantation, dUCBT). Following dUCBT, donor(s) hematopoietic stem cells (HSC) can be detected in the peripheral blood of the recipient as soon as 14 days post-transplantation. Sustained engraftment of HSC from one or both donors can be observed- dominance or mixed chimerism respectively, although single donor unit dominance has been observed in over 85% of patients. The underlying biology, which accounts for the interactions both between the two infused UCB units- cooperative or competitive, and with the recipient's immune system, has not been elucidated.
在过去二十年中,脐带血(UCB)移植(UCBT)越来越多地用于治疗各种恶性和良性血液疾病及其他疾病。限制UCB用于低体重受者(主要是儿童和青少年)的主要因素是其祖细胞含量低。人们已经探索了各种替代方法来克服这一困难,包括移植两个UCB单位(双脐带血移植,dUCBT)。dUCBT后,移植后14天即可在受者外周血中检测到供体造血干细胞(HSC)。可以观察到来自一个或两个供体的HSC持续植入——分别为单一供体主导或混合嵌合体,尽管超过85%的患者观察到单一供体单位主导。两个输入的UCB单位之间相互作用(协同或竞争)以及与受者免疫系统相互作用的潜在生物学机制尚未阐明。